SCHEMBL4928688

SCHEMBL4928688

Cn1ccnc1N1CCN(c2cc(-c3ccc(F)c(Cl)c3)cc(N3CCOCC3)n2)CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 3/20 0.43
PIK3CA P42336 4/20 0.43
PIK3CD O00329 3/20 0.43
PIK3CB P42338 3/20 0.43
CYP3A4 P08684 3/20 0.41
AKT1 P31749 3/20 0.41
PIK3CG P48736 2/20 0.41
PRKDC P78527 1/20 0.41
KCNH2 Q12809 1/20 0.41
GRM2 Q14416 1/20 0.40
AURKA O14965 1/20 0.39
AURKB Q96GD4 1/20 0.39
AOC3 Q16853 1/20 0.39
KDM4E B2RXH2 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
LRRK2 Q5S007 1/20 0.38
MEN1 O00255 1/20 0.37
NPC1 O15118 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4929517 0.81 HRH4 (0.41) PRKDCKCNH2TGFBR1
SCHEMBL3889976 0.79 NMT1 (0.48) CNR2PIK3CAPIK3CDPIK3CBCYP3A4
SCHEMBL908469 0.79 CNR2 (0.50) CNR2PIK3CAPIK3CDPIK3CBCYP3A4
SCHEMBL3878686 0.75 HSD11B1 (0.47)
SCHEMBL4930783 0.74 CHRM4 (0.38)
SCHEMBL4930774 0.74 CHRM4 (0.38)
SCHEMBL4037090 0.73 ALDH1A1 (0.50) PIK3CAPRKDCKDM4ECYP1A2CYP2C19
SCHEMBL4926985 0.72 HRH4 (0.44) KDM4E
SCHEMBL907702 0.70 P2RY12 (0.55)
SCHEMBL908448 0.69 PIK3CA (0.48) CNR2PIK3CAPIK3CDPIK3CBCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080124384-A1 Heteroaryl Substituted Piperazinyl-Pyridine Analogues NEUROGEN CORPORATION 2008-05-29 US disclosed
US-20080124384-A1 Heteroaryl Substituted Piperazinyl-Pyridine Analogues NEUROGEN CORPORATION 2008-05-29 US disclosed
US-20080124384-A1 Heteroaryl Substituted Piperazinyl-Pyridine Analogues NEUROGEN CORPORATION 2008-05-29 US disclosed
EP-1838703-A2 HETEROARYL SUBSTITUTED PIPERAZINYL-PYRIDINE ANALOGUES NEUROGEN CORPORATION (US) 2007-10-03 EP disclosed
WO-2006078992-A2 HETEROARYL SUBSTITUTED PIPERAZINYL-PYRIDINE ANALOGUES NEUROGEN CORPORATION (US) 2006-07-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080124384-A1 Heteroaryl Substituted Piperazinyl-Pyridine Analogues PIGO, GPR52, GPR88 CNR2 37/4885PIK3CA 756/4885PIK3CD 1100/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.